✦ LIBER ✦

Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function

✍ Scribed by Sukru Emre; Gabriel Gondolesi; Kamil Polat; Menahem Ben-Haim; Tarik Artis; Thomas M. Fishbein; Patricia A. Sheiner; Leona Kim-Schluger; Myron E. Schwartz; Charles M. Miller

Book ID: 111722995
Publisher: John Wiley and Sons
Year: 2001
Tongue: English
Weight: 210 KB
Volume: 7
Category: Article
ISSN: 1527-6465
DOI: 10.1053/jlts.2001.22455

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomized controlled trial of late co

A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function

✍ Christopher J.E. Watson; Alexander E.S. Gimson; Graeme J. Alexander; Michael E.D 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 307 KB 👁 1 views

Renal impairment is common in patients after liver transplantation and is attributable in large part to the use of calcineurin inhibitor (CNI)-based immunosuppression. We sought to determine whether conversion to sirolimus-based immunosuppression was associated with improved renal function. In a sin

Corticosteroid-free immunosuppression wi

Corticosteroid-free immunosuppression with daclizumab in HCV+ liver transplant recipients: 1-year interim results of the HCV-3 study

✍ Goran B.G. Klintmalm; W. Kenneth Washburn; Steven M. Rudich; Thomas G. Heffron; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 246 KB

This work is a 1-yr interim analysis of a prospective, randomized, multicenter trial evaluating the effect of corticosteroid-free immunosuppression on hepatitis C virus-positive (HCV ϩ ) liver transplant recipients following liver transplantation (LT). Patients received tacrolimus and corticosteroid

Preserving renal function in liver trans

Preserving renal function in liver transplant recipients with rabbit anti-thymocyte globulin and delayed initiation of calcineurin inhibitors

✍ Iman Bajjoka; Lama Hsaiky; Kimberly Brown; Marwan Abouljoud 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 120 KB

Early renal dysfunction following liver transplantation is associated with increased morbidity and mortality. To evaluate the impact of delayed initiation of calcineurin inhibitor on renal function, we conducted a retrospective study comparing 118 liver transplant recipients who received rabbit anti

Use of sirolimus in liver transplant rec

Use of sirolimus in liver transplant recipients with renal insufficiency: A systematic review and meta-analysis

✍ Sumeet K. Asrani; Michael D. Leise; Colin P. West; M. Hassan Murad; Rachel A. Pe 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 419 KB 👁 1 views

Sirolimus is used in patients with renal insufficiency after liver transplantation (LT) and especially in those with calcineurin inhibitor (CNI)-associated nephrotoxicity. We conducted a systematic review of all randomized controlled trials and observational studies to test the hypothesis that the u

Improvement in renal function and reject

Improvement in renal function and rejection control in pediatric liver transplant recipients with the introduction of sirolimus

✍ Adela T. Casas-Melley; Kathleen P. Falkenstein; Louise M. Flynn; Valerie L. Zieg 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB

Improvement of renal function after the

Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction

✍ Javier F. Castroagudín; Esther Molina; Rafael Romero; Esteban Otero; Santiago To 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 141 KB 👁 1 views

Chronic renal dysfunction is a frequent and severe complication in solid-organ transplant recipients. Calcineurin inhibitors (CNIs) are the main pathogenic factors of renal dysfunction. Switching from CNIs to nonnephrotoxic drugs, such as mammalian target of rapamycin inhibitors (everolimus and siro